Delivering on the promise of RNA therapeutics

SiSaf’s Bio-Courier technology combines a proprietary bioabsorbable silicon matrix with surface lipids and amino acids, a structure that addresses several of the major limitations and concerns associated with lipid nanoparticles to deliver RNA therapeutics.

Silicon’s durable electrostatic potential helps bind and stabilise RNA reducing the need for potentially toxic cationic lipids and averting the risk of premature detachment of RNA.

The high structural integrity of the silicon metalloid matrix prevents collapse on freeze drying and reduces the need for PEGylation, a key step to avoid the need for ultra-cold supply chain storage.

Partnered

We are partnered with a leader in ophthalmic genetic disease, Avellino Labs USA, to develop the world’s first eye drop RNA interference therapy and CRISPR cas 9 gene editing cure for Corneal Dystrophy.